Support the international community to fight counterfeit drugs with digital tools
The development of biotechnology holds tremendous promises for the developing world
We pledge to provide regulatory, advisory and research expertise to improve the quality of your life
Biotechnology involves transformative technologies for medicine, environment and agriculture. The use of living systems and organisms to make or develop products has increased dramatically over the recent years.
An increasing demand for biotechnology-based diagnostics and therapeutics solutions such as DNA sequencing, tissue engineering and regeneration, cell-based assay promotes funding to support R&D and new product development endeavours.
2017 was a record year for biotech investments. VC funding for digital health accounted for nearly $4.5 billion which is approximately 109% up in comparison with 2016.
According to our estimates, the world biotechnology market value will cross $2 trillion in 2018 with 67% of manufacturers revenue coming from the sales of biotech and pharmaceutical products.
We expect the global biotech industry to register a stable annual growth of around 4.9% during the next 5 years.
Genome analysis cost has significantly reduced because of the emergence of second and third generation sequencing technologies (NGS). As a whole genome scanning cost falls the personalised medicine grows, a new understanding of the genetic variation of individuals is appeared. Moreover, unidentified vast regions of DNA now are clear and unlocked.
Medical scientists and drug developers have tremendous opportunities to test drugs in the lab as they see how stem cells are able to grow into any of the body’s specialised cells. However, their major goal and perspective is to rise to an era of regenerative medicine where life-altering injuries and deadly diseases are not just treated, but cured.
Commonly, the basic cure for a specific disease is when drugs interact by binding with proteins. Some clinical methods solves this problem by acting directly on genes that are responsible for producing the deleterious protein. For accomplishing this there are number of technologies that introduce a gene through a viral vector, RNAi, antisense or use so-called zinc finger proteins.
MicroRNA is a new way of diagnosing and treating disease. MicroRNAs prevents the translation of messenger RNA into proteins by breaking down of messenger RNA. The absence or presence of specific microRNAs in various cells is held by specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease.
Growing prevalence of chronic diseases heightening the demand for new drug development is one of the key factors of segment growth during the next 5-year period. The combination of biotechnology and pharmaceutical results in the development of effective and advanced therapies used to treat many life threatening diseases.
Intelligent and implantable devices serve medicine with monitoring the health of an individual and, in some cases, alert or even respond to changing conditions within the body.
Biotechnology gives good grounds for expecting cheaper and safer vaccines. Alternatively DNA vaccines use a piece of genetic code for a pathogen instead of using a weakened or killed virus use a piece of genetic code for a pathogen. Traditional methods involve using eggs to grow vaccines. DNA vaccines can be made cardinally quicker and production is more bigger and innovative.
Synthetic biology includes a construction of DNA as a basis for building organisms that can perform specific tasks. It is a major part in developing new biofuels that can break the world’s addiction to petroleum. This sphere draws a great attention for its potential in providing cleaner and renewable sources of fuel. Thus it is changing everything from the way drugs are made to the way industrial goods are manufactured.
Systems biology focuses on understanding the interaction between a series of genes and their interactions with proteins. Advances in computing, the falling cost of genetic analysis, and other technological advances made this data-intensive approach possible.
Accelerated breakthroughs in Adoptive T-cell therapies will contribute to the growth of immuno-oncology market during the next 10 years.
Bacteriorhodopsin is a photosensitive protein of purple membranes of Halobacterium salinarum microorganisms living in salt lakes, where the salt concentration is 6 times higher than in the seawater.
Treatment of psoriasis, asthma, conjunctiviti
The RESTET skin regeneration system is the flagship project focused on the research and development of next generation medicines based on bacteriorhodopsin - one of the most promising means of fighting against diseases such as psoriasis, atopic dermatitis, neurodermatitis and acne. RESTET is a unique breakthrough in the field of molecular biocosmetology and has no side effects. The methods of treatment are effective for any age, sex, duration of skin lesions. The unique process of the synthesis of bacteriorhodopsin has been patented in different countries, including Germany, France, China, Iran and South Korea.
Total Supply12 000 000 000 GEN
Hard Cap70 000 000 $
Soft Cap20 000 000 $
Token price0.01 $
Primary Scientific and Medical Research
Ecosystem and Platform Development
Low Level Design Launch
Ecosystem Alpha Version Testing
Smart-Contract Development and Testing. Grant Application Program Launch
Ecosystem Complete Version Launch
Official Public GENEXI Accelerator Report
Further Ecosystem Development and Scaling
President of JFSC Atlant and a founder of Genexi Foundation with over 12 years of professional experience in investment management. Alexey is a serial entrepreneur who has built multiple successful companies in financial and real estate sector. His current focus lies within venture capital business, where he encourages innovation and facilitates entrepreneurship providing both his management and marketing expertise to young entrepreneurs. He seeks to make investments that solve critical social and environmental issues.
Head of Medical Research
Head of Finance
Head of Operations
Head of Strategy
Head of Business Development
Head of Research
Head of HR
Head of Marketing
Head of IT
Technical Support Lead
07 February 2018
Genexi at Blockchain Economic Forum 2018 in Singapore
10 March 2018
Blockchain Leadership Summit | March 9th | Zurich, Switzerland
18 April 2018
World Blockchain Forum — Investments & ICOs — Dubai
Genexi co-founder and CEO Alexey Zhelyaskov attended the Blockchain Economic Forum, held on 4-6 February, 2018 in Singapore. The Blockchain Economic Forum accentuated the growing influence of the crypto economy on global economic processes and facilitated a productive dialogue on the most crucial topics. The presence of Vincente Fox, the former President of Mexico, should be noted.
The Blockchain Leadership Summit took place on 9 March, 2018 in Zurich, Switzerland. It is widely regarded as one of the main conferences for experts and visionaries of the blockchain industry. Experts from the real sector, pioneers of the digital economy, investment bankers and officials from Switzerland, Liechtenstein, Kazakhstan, and Russia were among the attendees.
The World Blockchain Forum, Investment & ICOs was held on 16 -17 April, 2018 in Dubai. Major market players joined the leaders of several countries, economic pioneers and enterprising investors hailing from all corners of the world in discussing the future of the financial world. According to Genexi co-founder and CEO Alexey Zhelyaskov, one of the conference's primary objectives was to understand the strategic tasks of blockchain globalization within the context of rapidly changing economic conditions.
We will contact you soon